Relmada Therapeutics, Inc. RLMD Accrued Fees For Issuance Of Common Stockin Dollars Per Share
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept rlmd:AccruedFeesForIssuanceOfCommonStockinDollarsPerShare.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s accrued fees for issuance of common stockin dollars per share.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s accrued fees for issuance of common stockin dollars per share?
- Relmada Therapeutics, Inc. (RLMD) reported accrued fees for issuance of common stockin dollars per share of $3.84M in Q1 2026.